Latest

Speculation about Obama’s as yet unknown choice for drug czar just got a little more interesting. Today, the White House  announced that ONDCP’s acting Deputy Director Patrick Ward will be promoted to acting director. In other words, the much-anticipated next drug czar will be…Patrick Ward.

He’s a former Air Force guy who joined the federal drug office to run foreign interdiction efforts:

… Mr. Ward is in frequent and close contact with relevant officials from the Drug Enforcement Administration, the United States Coast Guard, the Central Intelligence Agency, and departments of Defense, Homeland Security, State, and Justice. Mr. Ward co-chairs the relevant National Security Council Policy Coordinating Committee on International Drug Control, and represents ONDCP at meetings of the NSC Deputies.

To put it mildly, Ward isn’t a public health specialist. He’s a drug warrior who knows how to fly fighter planes. He’s everything we’re hoping to avoid with Obama’s theoretically pending drug czar nomination.

So what the hell is going on here? I have no idea. With only a week left in office, there’s no way Bush did this without a nod from the Obama camp. It’s become increasingly clear that Obama isn’t ready to fill the position, so I guess someone’s gotta do it. An interim appointment suggests that we’ll be waiting a while for Obama’s choice, and in the meantime, we’ll have a full-blown drug warrior running the show.

That sucks, and it’s Obama’s fault, but what can really be said about it? Jim Ramstad’s name was floating around, but mounting opposition appears to have disqualified him for good reasons. I’ll take a couple months of Patrick Ward if it means we get someone better down the road, but it’s still hard to imagine Obama selecting someone I could support.

If nothing else, the fact that the drug czar appointment process has gotten so drawn out and confusing is certainly a result of the potent controversy now surrounding the position itself. I believe Obama recognizes that ONDCP is a seriously flawed institution and he’s trying to reconcile that with his perceived political obligations. That’s fine, but the longer he leaves the same people calling the shots at the drug czar’s office, the further he’ll find himself from the drug policy "paradigm shift" he proposed on the campaign trail.

Update: Pete Guither reminds me that this won’t be the first time we’ve had a temporary drug czar, so maybe it’s not as odd as I’ve made it sound. Still, I think it’s interesting that drug czar appointments get handled this way. The position just isn’t taken that seriously, either by the administration or the press. Maybe it wouldn’t be that way if there were a greater perception of flexibility in our drug policy, such that one drug czar could be really different than another.

Fortunately, this time the policy issues at stake are more visible than ever before. The President-elect has made some pretty strong statements about our drug policy and the madness of the last 8 years has solidified numerous coalitions that will vigorously oppose anyone who doesn’t promise big changes at the drug czar’s office.

WASHINGTON, D.C. - The Bush administration struck a parting shot to legitimate science today as the Drug Enforcement Administration (DEA) refused to end the unique government monopoly over the supply of marijuana available for Food and Drug Administration (FDA)-approved research.  DEA's final ruling rejected the formal recommendation of DEA Administrative Law Judge (ALJ) Mary Ellen Bittner, issued nearly two years ago following extensive legal hearings.

"With one foot out the door, the Bush administration has once again found time to undermine scientific freedom," said Allen Hopper, litigation director of the American Civil Liberties Union Drug Law Reform Project. "In stubbornly retaining the unique government monopoly over the supply of research marijuana over the objections of DEA's own administrative law judge, the Bush administration has effectively blocked the proper regulatory channels that would allow the drug to become a wholly legitimate prescription medication."

The DEA ruling constitutes a formal rejection of University of Massachusetts at Amherst Professor Lyle Craker's petition, filed initially June 24, 2001, to cultivate research-grade marijuana for use by scientists in FDA-approved studies aimed at developing the drug as a legal, prescription medication. [ACLU]

Marijuana is bad and we are powerful, so f**k you. Furthermore…f**k you. And in conclusion, based on the aforementioned facts…f**k you.